AWR reported Q1 2026 results on May 6, just after the close — and the setup heading into the number was already complicated. The stock dropped 4.1% on the week to $76.20, slightly worse than close peers, arriving at earnings with the only active analyst rating on it a "sell" and the Street consensus barely above the current price.
The results themselves were mixed. EPS came in at $0.76, a penny short of the $0.77 estimate. Revenue of $169.2 million, however, beat the $157.0 million forecast by a meaningful margin — a revenue beat that partially offsets the earnings miss but does little to silence the bears. On the same day, the company declared a regular quarterly dividend of $0.50 per share, consistent with its historically reliable payout record. That income story is one of the few unambiguous positives in the setup.
Options positioning is more relaxed than usual, pointing to limited fear heading into the print. The put/call ratio slipped to 0.33 — slightly below its 20-day average of 0.37 and well off the 52-week high of 0.94. That is a modestly call-skewed setup: investors were not scrambling for downside protection in the days before the result. What's interesting is that the PCR had been running higher through most of April — near 0.44-0.48 during the mid-month tariff-noise period — then eased sharply in the last two weeks of April as the broader tape calmed. The current level is close to the low end of the year's range, which reflects complacency more than conviction.
Short interest does not tell an aggressive story here. At 2.1% of free float — down 13% over the past month and now near its lowest level of the year — short sellers have actually been reducing exposure. Borrow conditions reinforce that: cost to borrow runs at just 0.44%, and availability remains extremely loose, with the lending pool barely touched at around 1% of available shares currently lent out. There is no short-squeeze pressure, and no sign that new shorts are building. The ORTEX short score of 32 is unexceptional — roughly in the middle of the universe on a 0-100 scale.
The Street is not enthusiastic. The only active rating in the data is a "sell" from B of A Securities, which downgraded AWR to Underperform in early February 2025 with a $71 target. Wells Fargo moved to Equal-Weight in May 2025 with an $84 target — but both of those actions are over a year old and should be treated as background rather than current positioning. With the stock at $76.20 and the mean price target at $76.00, the Street collectively sees essentially zero return potential from current levels. The P/E sits near 22.4x on a trailing basis, with EV/EBITDA around 14.7x — reasonable multiples for a regulated water utility, but not cheap enough to attract buyers when earnings momentum is flat. The EPS surprise score of 66 (out of 100) suggests the company has historically beaten estimates at a decent rate, which may cushion the market's reaction to the Q1 miss.
The institutional holder base is stable and dominated by passive money — BlackRock holds 17.8% of shares, Vanguard 12.7%, with both adding modestly in recent reporting periods. On the insider side, a cluster of executive sales on March 13 — including the CEO and CFO selling at $74.44 — is worth noting as context, though the total values involved were relatively modest and routine compensation-related activity is the likely explanation. Peers also sold off on the week: CWT fell 7.5%, WTRG dropped 5.4%, and AWK lost nearly 5% — suggesting the move in AWR was broadly sector-driven rather than name-specific.
The key question after the May 6 close is how the market interprets the revenue beat relative to the EPS miss — and whether guidance for the rest of 2026 shifts the calculus from a sector-neutral to a name-specific story.
See the live data behind this article on ORTEX.
Open AWR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
